HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

HUTCHMED (China) LimitedNASDAQ: HCM

EBITDA · Q2 FY2025 · quarter ended Jun 2025

EBITDA turns positive

Q2 FY2025 EBITDA was $1.3M, compared with -$10.63M a year earlier. Trailing-twelve-month EBITDA was -$7.49M.

Context

  • EBITDA amounted to 7.5% of revenue in FY2025, up 2.5 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 16 analysts of $92.11M (+322.6%) for the fiscal year ending Dec 2026, a step up from the -31.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2025
$1.3M+0.0% QoQ
Last fiscal yearDec 2025
-$41.38M-31.9% YoY
LTMJun 2025
-$7.49M+93.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+112.2%-925.1%-1037.3 pp
1 year-31.9%+322.6%+354.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(41.38M) USD
Year-over-year change
-31.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +93.2% is the 2nd highest of 9, against a peer median of +20.8%.
  • EBITDA amounts to 1.2% of revenue for HCM, versus a peer median of 40.3%.
HCM Competitors
EBITDA for HCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$2.07B USD+52.6%+43.2%35.5%
GMABGenmab A/SLTM Jun 2026$1.22B USD—-43.3%29.5%
EXELExelixis, Inc.LTM Jul 2026$1.05B USD+28.1%+53.4%43.0%
LEGNLegend Biotech CorporationLTM Sep 2026$99.55M USD+154.3%—7.3%
HCMHUTCHMED (China) LimitedLTM Jun 2025-$7.49M USD+93.2%—1.2%
ANLAdlai Nortye Ltd.LTM Jun 2024-$63.57M USD——979.5%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-$135.46M USD+55.2%—60.1%
ZLABZai Lab LimitedLTM Jun 2026-$168.8M USD+13.6%—37.5%
RCUSArcus Biosciences, Inc.LTM Jun 2026-$419M USD-48.6%—358.1%
BNTXBioNTech SELTM Jun 2026-€941.06M EUR-2167.6%—35.6%
AAPGAscentage Pharma Group InternationalFY2025-CN¥1.1B CNY-360.8%—196.1%
Peer median (excluding HCM) —+20.8%+43.2%40.3%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue356.13M426.41M838M630.2M549.96M
Cost of Revenue258.23M311.1M384.45M348.88M337.24M
Gross Profit97.89M115.31M453.55M281.32M212.72M
Gross Margin27.5%27.0%54.1%44.6%38.7%
Research & Development207.45M267.59M303.06M213.37M164.15M
Selling, General & Admin127.13M136.11M133.18M112.91M103.3M
Operating Expenses426.21M523M436.23M321.93M267.45M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
EBITDA(207.96M)(401.11M)26.58M(31.36M)(41.38M)
EBITDA Margin-58.4%-94.1%3.2%-5.0%-7.5%
Operating Income(328.32M)(409.77M)18.38M(43.71M)(54.73M)
Operating Margin-92.2%-96.1%2.2%-6.9%-10.0%
Interest Income2.08M9.6M36.15M40.08M50.01M
Interest Expense592K652K759K2.87M2.87M
Other Income / Expenses173.19M51.52M87.23M89.07M577.45M
Income Before Tax(155.33M)(360.24M)105.6M45.36M522.72M
Pre-Tax Margin-43.6%-84.5%12.6%7.2%95.0%
Income Tax Expense11.92M(283K)4.51M7.19M63.78M
Net Income(194.65M)(360.84M)100.78M37.73M458.12M
Net Margin-54.7%-84.6%12.0%6.0%83.3%
EPS (Basic)(1.25)(2.15)0.600.222.65
EPS (Diluted)(1.25)(2.15)0.600.222.60
Weighted Avg Shares158.54M169.43M169.93M171.07M171.66M
Weighted Avg Shares (Diluted)158.54M169.43M173.84M174.57M174.58M

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.